192 related articles for article (PubMed ID: 16485128)
1. Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas.
Ciesielski MJ; Apfel L; Barone TA; Castro CA; Weiss TC; Fenstermaker RA
Cancer Immunol Immunother; 2006 Dec; 55(12):1491-503. PubMed ID: 16485128
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma.
Ciesielski MJ; Kozbor D; Castanaro CA; Barone TA; Fenstermaker RA
Cancer Immunol Immunother; 2008 Dec; 57(12):1827-35. PubMed ID: 18438666
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of murine bone marrow-derived dendritic cells infected with xenogeneic livin alpha recombinant adenoviral vectors against Lewis lung carcinoma.
Xie J; Xiong L; Tao X; Li X; Su Y; Hou X; Shi H
Lung Cancer; 2010 Jun; 68(3):338-45. PubMed ID: 19671483
[TBL] [Abstract][Full Text] [Related]
4. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic.
Ciesielski MJ; Ahluwalia MS; Munich SA; Orton M; Barone T; Chanan-Khan A; Fenstermaker RA
Cancer Immunol Immunother; 2010 Aug; 59(8):1211-21. PubMed ID: 20422411
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors.
Nagaraj S; Pisarev V; Kinarsky L; Sherman S; Muro-Cacho C; Altieri DC; Gabrilovich DI
J Immunother; 2007; 30(2):169-79. PubMed ID: 17471164
[TBL] [Abstract][Full Text] [Related]
6. Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein.
Cho HI; Kim EK; Park SY; Lee SK; Hong YK; Kim TG
Cancer Lett; 2007 Dec; 258(2):189-98. PubMed ID: 17931768
[TBL] [Abstract][Full Text] [Related]
7. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.
Zeis M; Siegel S; Wagner A; Schmitz M; Marget M; Kühl-Burmeister R; Adamzik I; Kabelitz D; Dreger P; Schmitz N; Heiser A
J Immunol; 2003 Jun; 170(11):5391-7. PubMed ID: 12759413
[TBL] [Abstract][Full Text] [Related]
8. Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model.
Siegel S; Wagner A; Schmitz N; Zeis M
Br J Haematol; 2003 Sep; 122(6):911-4. PubMed ID: 12956760
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.
Prins RM; Odesa SK; Liau LM
Cancer Res; 2003 Dec; 63(23):8487-91. PubMed ID: 14679014
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong CD4+ T cell immunity to mouse survivin.
Charalambous A; Oks M; Nchinda G; Yamazaki S; Steinman RM
J Immunol; 2006 Dec; 177(12):8410-21. PubMed ID: 17142738
[TBL] [Abstract][Full Text] [Related]
11. Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma.
Kim CH; Woo SJ; Park JS; Kim HS; Park MY; Park SD; Hong YK; Kim TG
Immunology; 2007 Dec; 122(4):615-22. PubMed ID: 17645496
[TBL] [Abstract][Full Text] [Related]
12. Novel cancer vaccine based on genes of Salmonella pathogenicity island 2.
Xiong G; Husseiny MI; Song L; Erdreich-Epstein A; Shackleford GM; Seeger RC; Jäckel D; Hensel M; Metelitsa LS
Int J Cancer; 2010 Jun; 126(11):2622-34. PubMed ID: 19824039
[TBL] [Abstract][Full Text] [Related]
13. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
[TBL] [Abstract][Full Text] [Related]
14. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas.
Ni HT; Spellman SR; Jean WC; Hall WA; Low WC
J Neurooncol; 2001 Jan; 51(1):1-9. PubMed ID: 11349874
[TBL] [Abstract][Full Text] [Related]
15. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.
Schmidt SM; Schag K; Müller MR; Weck MM; Appel S; Kanz L; Grünebach F; Brossart P
Blood; 2003 Jul; 102(2):571-6. PubMed ID: 12576330
[TBL] [Abstract][Full Text] [Related]
16. [Experimental study on activating antileukemic T cells by vaccination with dendritic cells pulsed with survivin].
Zhang XH; Xia LH; Liu ZP; Wei WN; Hu Y; Song SJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):66-9. PubMed ID: 12667293
[TBL] [Abstract][Full Text] [Related]
17. Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models.
Zhu K; Qin H; Cha SC; Neelapu SS; Overwijk W; Lizee GA; Abbruzzese JL; Hwu P; Radvanyi L; Kwak LW; Chang DZ
Vaccine; 2007 Nov; 25(46):7955-61. PubMed ID: 17933439
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen.
Croce M; Meazza R; Orengo AM; Fabbi M; Borghi M; Ribatti D; Nico B; Carlini B; Pistoia V; Corrias MV; Ferrini S
Cancer Immunol Immunother; 2008 Nov; 57(11):1625-34. PubMed ID: 18324400
[TBL] [Abstract][Full Text] [Related]
19. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma.
Van Houdt WJ; Haviv YS; Lu B; Wang M; Rivera AA; Ulasov IV; Lamfers ML; Rein D; Lesniak MS; Siegal GP; Dirven CM; Curiel DT; Zhu ZB
J Neurosurg; 2006 Apr; 104(4):583-92. PubMed ID: 16619663
[TBL] [Abstract][Full Text] [Related]
20. Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice.
Lladser A; Párraga M; Quevedo L; Carmen Molina M; Silva S; Ferreira A; Billetta R; G Quest AF
Immunobiology; 2006; 211(1-2):11-27. PubMed ID: 16446167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]